← Back to Clinical Trials
Recruiting NCT07200453

NCT07200453 Evaluation of an Interactive E-learning Environment to Enhance Digital Health Literacy in Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07200453
Status Recruiting
Phase
Sponsor Universitätsklinikum Hamburg-Eppendorf
Condition Neoplasms
Study Type INTERVENTIONAL
Enrollment 660 participants
Start Date 2025-01-16
Primary Completion 2025-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
intervention group 1.1 - e-learningintervention-group 1.2 - e-learningintervention-group 1.3 - e-learning

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 660 participants in total. It began in 2025-01-16 with a primary completion date of 2025-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to create and test an online learning tool to help people with cancer improve their skills in finding and understanding health information online. The main question it aims to answer is: • Do people with cancer who use the online learning tool improve their skills more than those who don't use the tool? The investigators will test this idea in a study. The investigators will put people into different groups by chance and compare the results. 660 people with cancer will participate. These people will be chosen to represent different types of cancer. * Group 1: Uses the online learning too (3 versions) * Group 2: Uses a PDF with the same information * Control Group: Receives no intervention What Participants Will Do: Use the online tool or PDF to learn how to find reliable cancer information online. Answer questions about their digital health skills before starting, after 2 weeks, and after 8 weeks. Development: Before the start of the main study the online tool will be developed and tested. The investigators will first show a prototype of the tool to two discussion groups and use their feedback to improve it. Then, experts and people with cancer will test the final version

Eligibility Criteria

Inclusion criteria: * cancer diagnosis * sufficient knowledge of the German language as all study content and questionnaires will be in German only * Participants must also have and be able to use a digital device (smartphone, tablet, PC, laptop, etc.) with an internet connection * Confirm consent to participate in the study Exclusion criteria: * Patients who are severely cognitively impaired due to their cancer or other illness * Patients who are unable to operate a digital device

Contact & Investigator

Central Contact

Lukas Lange-Drenth, Dr.

✉ lu.lange@uke.de

📞 +49 (0) 40 7410-56811

Principal Investigator

Holger Schulz, Prof.

PRINCIPAL INVESTIGATOR

Universitätsklinikum Hamburg-Eppendorf

Frequently Asked Questions

Who can join the NCT07200453 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07200453 currently recruiting?

Yes, NCT07200453 is actively recruiting participants. Contact the research team at lu.lange@uke.de for enrollment information.

Where is the NCT07200453 trial being conducted?

This trial is being conducted at Hamburg, Germany.

Who is sponsoring the NCT07200453 clinical trial?

NCT07200453 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The principal investigator is Holger Schulz, Prof. at Universitätsklinikum Hamburg-Eppendorf. The trial plans to enroll 660 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology